Harmony Biosciences Holdings, Inc. Profile Avatar - Palmy Investing

Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive day…
Biotechnology
US, Plymouth Meeting [HQ]
HRMY/Financial Reporting

Income Statements

6 Sheets · Starting from 2023
In Million USD. Margins, Growth Rates In %
Metric 2018 2019 2020 2021 2022 2023
Revenue
- - 5.00 159.00 305.00 437.00 582.00
EPS
-0.81 -2.48 -0.91 0.60 3.07 2.17
Profit
- - 4.00 132.00 249.00 354.00 460.00
Pre Tax
-39.00 -151.00 -36.00 37.00 104.00 173.00
ETR
-3.86 -4.00 -40.36 7.56 -73.35 25.69
Net
-39.00 -158.00 -51.00 34.00 181.00 128.00
EBITDA
-41.00 -142.00 13.00 87.00 120.00 231.00
Operating Income
-41.00 -145.00 3.00 68.00 120.00 192.00
Interest Income
- - 6.00 28.00 - - 3.00 14.00
Loss
-41.00 -151.00 -142.00 -217.00 -317.00 -389.00
Cost of Revenue
- - -1.00 -27.00 -55.00 -83.00 -121.00
Operating Expenses
-41.00 -150.00 -115.00 -162.00 -234.00 -268.00
Depreciation and Amortization
- - -3.00 -10.00 -18.00 -23.00 -24.00
Interest Expenses
- - -6.00 -28.00 -23.00 -15.00 -23.00
Other Expenses
-1.00 -6.00 -40.00 -31.00 -15.00 -9.00
WA Shares Outstanding
49.00 63.00 56.00 57.00 59.00 59.00
End of HRMY's Analysis
CIK: 1802665 CUSIP: 413197104 ISIN: US4131971040 LEI: - UEI: -
Secondary Listings
HRMY has no secondary listings inside our databases.